JournalLicensing

Licensing a government-funded patent: what the funding agency's rules mean for a company

Government funded patent license in India: how BIRAC, ICMR, DST and ANRF rules shape ownership, royalty, march-in rights and transfer, with a rupee example.

By Sahil Sheikh, Regd. Patent & Trademark Agent, cRTTP 7 min read

Part of the guide Licensing technology from Indian institutions: the complete guide for companies

Short answer

When a company licenses a patent from government-funded research in India, the funder's grant terms can travel with it. BIRAC's BIPP and SBIRI terms set a 5% to 8% royalty on net sales, and for nationally important projects add a royalty-free licence for BIRAC and march-in rights. ICMR extramural grants make ICMR a joint owner with the host institute.

A lot of the technology worth licensing in India was paid for, at least in part, by a government grant. That money usually comes with terms, and the terms do not disappear when the patent is licensed to you. Before you sign, you need to know which agency funded the work, which scheme, and what that scheme's guidelines reserve for the funder.

India has no single statute on this. The Protection and Utilisation of Public Funded Intellectual Property Bill, 2008 was introduced in the Rajya Sabha on 15 December 2008 and withdrawn on 8 December 2014. So the rules live in grant documents, scheme by scheme. This post covers the ones a company meets most often.

How do you find out who funded the patent?

Ask the licensor, in writing, and ask for the sanction letter or grant agreement. Also look for clues: the acknowledgement section of the inventors' papers, the project title on the institution's website, and the patent specification itself, which sometimes names the funding. A good patent due diligence checklist includes this question for a reason.

What do the main funders reserve?

Funder and scheme Who owns new IP What the funder keeps Royalty to funder Transfer and other limits
BIRAC BIPP (2025 guidelines) The recipient of funds, jointly unless agreed otherwise Royalty-free, non-exclusive, irrevocable licence for public interest or government use, for nationally important projects 5% of annual net sales (7% for distinct products from multiple projects) Prior written permission to transfer or sell; for nationally important projects, march-in rights, under which BIRAC can also require manufacture and sale in India
BIRAC SBIRI The recipient of funds, as in BIPP Royalty-free licence for nationally important projects, as in BIPP 7% of annual net sales (8% for distinct products from multiple projects), ending once payments reach 1.2 times the grant-in-aid Prior written permission to transfer, except for nationally important projects; march-in for those projects
BIRAC BIG (Version 8, July 2020) Not set out in the guidelines Payment if intermediate technology or know-how is transferred to a third party 5% of net sales until total royalty equals the grant As agreed with BIRAC
ICMR extramural research Jointly the Council and the host institute of the PI Joint owner's rights As agreed with ICMR ICMR's commercialisation rules apply
ICMR technology development collaboration (2024) IP generated during licensing or co-development jointly owned by ICMR and the licensee Royalty-free, non-exclusive, irrevocable licence; march-in where demand is not met at a reasonable price 2% of net sales for licensing, with a 10-year sunset Eligibility needs at least 51% of shares held by Indian citizens; foreign transfers need ICMR approval
ANRF ATRI Set by the partners' agreement A signed copy of the IPR and licensing agreement goes to ANRF before the first instalment Not stated As agreed between partners
DST (TSD programme terms) Not set out in the grant terms Assets bought from the grant belong to the Government of India; results to be protected before publication Not stated Follow DST's technology transfer guidelines

Sources: BIRAC's BIPP 2025 guidelines, SBIRI scheme document and BIG guidelines; ICMR's extramural guidelines and technology development collaboration guidelines; ANRF's ATRI document; DST's TSD terms and conditions. We could not find a DST-wide revenue share rule, so none is stated here.

What do march-in rights mean for a licensee?

March-in is the clause that should worry a licensee most, because it can move the technology to someone else.

Under BIRAC's BIPP and SBIRI guidelines, march-in rights sit in the terms for projects designated nationally important. They apply if the product is not commercialised within 4 years of project completion, or if public or national needs are not met. BIRAC can then require the know-how to be transferred to other entrepreneurs, and if the recipient refuses, it can require the IP to be assigned to BIRAC. Ask the licensor whether its project carried that designation. ICMR's 2024 collaboration guidelines provide march-in "where demand-supply gap is not being met at a reasonable price", and also where the technology is not commercialised within two years of licensing.

For you, that means two things. Check how much of the four-year window is left when you sign. And write your licence so that the licensor must tell you of any notice from the funder, with a right for you to cure, for example by launching or by supplying at a reasonable price.

Illustration: the BIRAC four-year commercialisation clock

Project endsClock startsFour years, for nationally important projects
Year 2You sign a licenceOnly two years of the window left
Year 3Pilot and approvalsRegulatory time eats the margin
Year 4March-in can applyIf the product is still not commercialised
Invented dates for a project designated nationally important.

Does the funder's royalty add to yours?

Often, yes. BIRAC's royalty is owed by the company that received the grant, on its net sales. If that company licenses the technology to you, it will usually want the BIRAC royalty passed through, on top of its own return. If an institution licenses ICMR co-owned IP to you, ICMR's share is decided in its own terms.

Worked example (invented figures). A startup received a BIPP grant and now licenses its patented diagnostic to your company. Your net sales in year one are ₹2 crore.

Payment Basis Year one
BIRAC royalty, passed through 5% of ₹2 crore ₹10 lakh
Startup's own royalty 4% of ₹2 crore ₹8 lakh
Total royalty 9% of net sales ₹18 lakh

Agree in writing whose net sales the BIRAC rate applies to, because the grant recipient's sales and the licensee's sales may be different numbers. If the BIRAC royalty is calculated on your sales, make the licence say so, and say that you pay it once only.

What about foreign companies and manufacturing in India?

For nationally important projects, the BIRAC march-in terms let BIRAC require that the product be manufactured and sold in India. ICMR's 2024 guidelines require at least 51% of the licensee's shares to be held by Indian citizens, and foreign or foreign-equity transfers need approval from the Competent Authority at ICMR. ICMR's 2024 IP policy, as we read it, also ties commercialisation to the Government of India's mandate on exploitation of IP by foreign parties.

If your company has foreign shareholding, or plans to manufacture abroad or sublicense to a foreign partner, raise it at the first meeting. It can decide whether the deal is possible at all.

The government's own rights

Separately from grant terms, section 100 of the Patents Act lets the Central Government, or a person it authorises in writing, use an invention for the purposes of government, and section 102 provides for acquisition of inventions and patents. These apply to any patent, funded or not. Some grant terms add a royalty-free licence for public purposes: ICMR's 2024 collaboration guidelines do, and BIRAC's do for nationally important projects. So an exclusive licence of government-funded IP is rarely exclusive against the government itself.

Five checks before licensing funded IP

1
FunderAgency, scheme and sanction letter
2
OwnershipRecipient, institute or joint with funder
3
Funder's rightsLicence, royalty, march-in, consent
4
EligibilityIndian shareholding, manufacture in India
5
Licence termsPass-through, notice and cure

Clauses to add to your licence

  • A warranty, or at least a disclosure schedule, listing every grant that funded the technology and the funder's reserved rights. Warranties and indemnity covers what institutions will give.
  • Confirmation that any funder consent needed for the licence has been obtained, with a copy attached.
  • A clear statement of any royalty passed through, and its base.
  • A duty on the licensor to forward any march-in or compliance notice within a fixed number of days.
  • Where ICMR is a joint owner, ICMR as a party or as a consenting owner. Joint patents explains why every co-owner matters.

Register the licence on Form 16 under section 69 once signed. Registration is not what makes it valid; section 68 does that, by requiring the licence in writing with all its terms and duly executed. But an unregistered licence is not admitted as evidence of your interest unless the Controller or a court directs otherwise. Patent licensing in India covers the steps.

My view is that funded IP is often the best value in Indian licensing, because the public has already paid for the early risk. The price is paperwork, and a licensee who reads the grant terms first will negotiate a better deal than one who learns them from a funder's letter later. I cannot say how often march-in has actually been used in India; I found no published record, and that uncertainty is itself a reason to draft for it.

If you are still searching for the right technology, Zernyx Hub has mapped patents from universities across India, with AI business insight on each.

Common questions

Does India have a law on publicly funded IP?

No single law. The Protection and Utilisation of Public Funded Intellectual Property Bill, 2008 was introduced in the Rajya Sabha on 15 December 2008 and withdrawn on 8 December 2014. The rules come instead from each funding agency's grant terms and guidelines, so you must read the specific scheme.

What are march-in rights in BIRAC funding?

Under BIRAC's BIPP and SBIRI guidelines, for projects designated nationally important, if the product is not commercialised within four years of project completion, or public or national needs are not met, BIRAC can require the know-how to be transferred to other entrepreneurs, with assignment of the IP to BIRAC as a fallback if the recipient refuses. A licensee of that technology should check the timeline before signing.

Who owns IP from an ICMR-funded university project?

Under ICMR's Guidelines for Extramural Research Programme, new IP generated in research supported by ICMR jointly belongs to the Council and the host institute of the principal investigator. A company licensing such a patent should expect both to be party to, or to consent to, the licence.

Can the government use a patent that a company has licensed?

Section 100 of the Patents Act lets the Central Government, or a person it authorises in writing, use an invention for the purposes of government, and section 102 provides for acquisition of inventions and patents. Some grant terms add a royalty-free licence for public purposes, such as ICMR's 2024 collaboration guidelines and BIRAC's terms for nationally important projects.

Sahil Sheikh
About the author

Sahil Sheikh, Regd. Patent & Trademark Agent, cRTTP

Chief IP & Technology Officer, Zernyx Innovations

Connect on LinkedIn

Find a technology you can own.

Search patented technologies from Indian universities and labs, check their readiness and license the right one on Zernyx Hub.

Explore Zernyx Hub

Keep reading

Looking for something else?